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Polymorphisms in genes of the innate immunity may modify the progression of CF
pulmonary disease and inﬂuence Pseudomonas aeruginosa (P.a.) colonisation.
SNPs analysis of genes contributing to the innate immunity [MBL2 (Mannose
binding lectin), MASP (MBL associated serine Protease)1→ 3, FCN (Ficolin)1→ 2,
LBP (Lipopolysaccharide-binding Protein), CD14, TLR (Toll-like receptor 1→ 10)]
was performed in 116 CF patients (6−44 y). A decline in FEV1 of 14% over a 6 y
period and FEV1 value of 70% were used to discriminate mild from more severe
affected adult patients (16 y). The frequency of single and combined SNPs in
well-deﬁned subgroups was compared.
In adults with a mean FEV1 lower than 70%, the combinations of SNPs of CD14
with TLR 10 (odds ratio [OR] 6.2), FCN 1 with TLR 5 (OR 6.2) and MASP 3 with
TLR 9 (OR 5.6) were signiﬁcant more common than those with mean FEV1 >70%.
The frequency of combination SNPs of MASP2 with TLR2 (OR 6.5) and MASP2
with TLR4 (OR 5.3) was signiﬁcantly higher in adults with more than 14% decline
in FEV1 compared to those with less than 14% decline. In P.a. colonised patients,
an increased frequency of combined SNPs of TLR1 with TLR6 (OR 3.6), LBP with
TLR6 (OR 3.6) and MBL2 with TLR6 (OR 3.4) was found. In general, the OR
for combined SNPs were higher than for the single SNPs and remained signiﬁcant
when the different groups were subdivided according to CFTR genotype.
Certain combinations of SNPs of genes of the innate immunity are more frequently
found in CF patients with a lower FEV1, a stronger decline in pulmonary function
and P. aeruginosa colonisation. Further studies are ongoing to conﬁrm these
observations.
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The clinical course of cystic ﬁbrosis (CF) varies widely among patients carrying the
same CFTR gene mutations supporting that additional genetic modiﬁers could affect
the CF phenotype. As inﬂammation is a central contributor to the pathogenesis of
CF lung disease, genes involved in the inﬂammatory response are potential modiﬁer
candidate genes. We examined the inﬂuence of 13 polymorphisms in 7 genes
involved in the inﬂammatory response (TNF, IL-1b , IL-1 receptor antagonist (RN),
IL-6, IL-8, IL-10 and TGF-b1), on disease progression in a group of 329 Caucasian
children with CF. The genotypes were tested for an association with changes in
lung function tests, Pseudomonas aeruginosa colonization and nutritional status
by multivariable analysis. We found a signiﬁcant association between TGF-b1
+869T/C variants and decline in lung function measured as FEV1 and FVC
(p = 0.004 and 0.02 respectively). IL-8 gene polymorphisms (−251A/T, +396G/T
and +781T/C) were associated with the occurrence of Pseudomonas aeruginosa
colonization (P< 0.02). To conclude, this study suggests that IL-8 variants may
inﬂuence Pseudomonas aeruginosa colonization in CF, however this need further
conﬁrmation. We also provide additional support to the results of other trials and
suggest an association between TGF-b1 variants and lung disease progression in
CF.
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Background: Disease severity in patients with cystic ﬁbrosis (CF) shows marked
variability not entirely based on the CFTR genotype. Mutations in other genes may
contribute, including various polymorphisms in a role of CF modiﬁers; one of them
may be transferrin (Tf), namely the C2 genetic variant. Besides, serum Tf is used
as a marker of hypoglycosylation (also noted in CF).
Methods: Over 110 children and adults with CF and 100 controls were studied.
Glycosylation degree (based on the ratio of Tf isoforms) and the type of Tf variant
(diverse electrophoretic mobility) were checked in subjects divided into groups
according to the CFTR genotype, P. aeruginosa infection, respiratory capacity
and pancreatic (in)sufﬁciency. Common isoelectric focusing followed by direct
immunoﬁxation with densitometric evaluation was used.
Results: No signiﬁcant hypoglycosylation was found in our set of CF patients,
however, substantial difference (p = 0.004) of the heterozygous C1C2 variant occur-
rence exists between healthy controls (16%) and CF subjects (41%). In all patients
with the Tf C1C2 genotype only the DF508 mutation was identiﬁed, in contrast to
subjects with other Tf variants. Most of CF patients were pancreatically insufﬁcient
and all presented respiratory symptoms.
Conclusions: Despite the unclear role of the Tf C2 in the CF pathogenesis,
identiﬁcation of a new independent genetic factor may be used as a marker of
patients at risk of more severe forms of the disease.
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Background: Computational methods have been developed to predict the molecular
consequences of amino acid substitutions on the basis of evolutionary conservation
or protein structure. However, their ability to predict disease pathogenesis, partic-
ularly in asymptomatic individuals (newborn screening) or in determining clinical
outcome, has not been well validated. We hypothesized that scores generated by
computational programs would offer a clinically useful substitute for functional
analysis. Mutations in the CFTR gene offer an ideal evaluative test bed, because
over 40% of the mutations are non-synonymous variants with largely unknown
functional consequences.
Methods: We tested the ability of three in silico tools (PANTHER, SIFT and
PolyPhen) to predict the pathogenic consequences of pre-selected missense CFTR
variants with a known range of clinical effects, including those that confer: (a) CF
disease or CFTR-associated disorder (CBAVD) or no disease and (b) pancreatic
sufﬁciency or pancreatic insufﬁciency in the CF patients.
Results: All three tools, failed to reliably predict mutations that confer CF disease,
CBAVD disease and no disease. Furthermore, there was no signiﬁcant correlation
between computed scores and pancreatic phenotypes, largely because of poor
predictions of pancreatic sufﬁciency.
Conclusion: Since these computational methods fail to predict the pathogenicity
of mutations with known functional effects, they are unlikely to predict the
consequences of rare or novel mutations. Therefore, current methods have little
or no clinical utility for establishing or excluding a CF diagnosis in screen-positive
infants, or predicting clinical outcomes in individuals with CF.
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